Treatment progress of multiple myeloma
10.3760/cma.j.cn115356-20200201-00028
- VernacularTitle:多发性骨髓瘤治疗进展
- Author:
Zeyu LIN
1
;
Wenming CHEN
Author Information
1. 首都医科大学附属北京朝阳医院血液科 100020
- From:
Journal of Leukemia & Lymphoma
2020;29(3):132-135
- CountryChina
- Language:Chinese
-
Abstract:
The clinical study of multiple myeloma at various stages has been reported at 2019 American Society of Hematology Annual Meeting. This article focuses on several key studies of the treatment of high-risk smoking multiple myeloma (HR-SMM), newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM), especially the chimeric antigen receptor T-cell (CAR-T) therapy, in order to guide clinical selection of better treatment options. However, most of these studies are phase Ⅰ-Ⅱ studies, and the median follow-up period is short, the long-term follow-up and the results of phase Ⅲ studies with enlarged samples are needed to further determine the effectiveness and safety of each treatment plan.
